𝔖 Bobbio Scriptorium
✦   LIBER   ✦

292. Cisplatin and 5-fluorouracil in recurrent, persistent or metastatic cervical carcinoma

✍ Scribed by E. Wachuła; A. Jagiełło-Gruszfeld; E. Szybicka-Flisikowska; M. Sikorska

Book ID
104441370
Publisher
Wielkopolskie Centrum Onkologii
Year
2003
Tongue
Polish
Weight
194 KB
Volume
8
Category
Article
ISSN
1507-1367

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Palliative treatment with low-dose conti
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type
✍ Abderrahim Fandi; Abdelkrim Taamma; Nacer Azli; Mounir Bachouchi; Bashar Yanes; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

## Background: Low-dose protracted continuous infusion (ci) 5-fluorouracil (5-fu), as proposed by lokich et al, has been reported to be active and well tolerated in colorectal and breast cancers. we initiated a phase ii trial with ci 5-fu in heavily pretreated undifferentiated carcinoma of the naso

Paclitaxel, cisplatin, and 5-fluorouraci
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi